Reports
Sale
Global Hemoglobinopathies Market Size, Share, Trends, Growth: By Hemoglobinopathy Type: Sickle Cell Disease, Thalassemia, Other Hemoglobinopathies; By Diagnosis Type: DNA Testing, Hemoglobin Electrophoresis, Complete Blood Count (CBC), Others; By Treatment Type; By End User; Regional Analysis, Supplier Landscape; 2024-2032
Global Hemoglobinopathies Market Outlook
The global hemoglobinopathies market size was valued at USD 6.9 billion in 2023, driven by the rising incidence of thalassemia and sickle cell anemia across the globe. The market is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032, with the values likely to rise from USD 7.5 billion in 2024 to USD 15.9 billion by 2032.
Global Hemoglobinopathies Market Overview
Hemoglobinopathies are a group inherited blood disorders, affecting hemoglobin in the red blood cells. They are often caused by genetic mutations that lead to alteration of hemoglobin structure, function, or production. Sickle cell anemia and thalassemia are amongst the most common types of hemoglobinopathies.
It is estimated that sickle cell anemia affects approximately 100,000 United States citizens, with a higher prevalence in Black or African American race (1 in every 365 individuals ). Consequently, the hemoglobinopathies market demand is on the rise to combat the rising incidence of diseases. The market growth is driven by advancements in treatment and diagnostics. Innovations and growth in gene therapy activities is one of the major market trends. In December 2023, the United States FDA approved Exa-cel , the first CRISPR treatment for sickle cell disease. Lovo-cel, developed by Bluebird Bio is another gene therapy accepted by the FDA and will be used to treat sickle cell anemia in patients. The increasing integration of novel technologies to aid impactful treatment alternatives is expected to drive market growth in coming years.
The hemoglobinopathies market share is also poised to elevate with rising emphasis on detecting the condition early. In June 2023, Florida Atlantic University released their latest research on developing a portable tool to diagnose and monitor sickle cell anemia. Based on electrical impedance sensor, the device can analyze the rate of cell sickling and the concentration of sickled cells in the body. It can assist in quality treatment and mitigate the comorbidities associated with the disease.
Global Hemoglobinopathies Market Trends
| Key Trends | Description |
| Rising Awareness via Screening Programs | To combat the rising incidence of hemoglobinopathies across the globe, many countries have started implementing new screening programs to detect any abnormalities at an early stage. |
| Surge in Strategic Partnerships and Collaborations | Rising partnerships between pharmaceutical companies, healthcare providers, and research institutions is a notable market trend. The collaborations are aimed at developing effective and precise solutions for patients. |
| Preference for Personalized Medicine | Tailoring treatment plans based on the genetic profile of the patient is a significant trend in the market. Precision medicine can help in minimizing side effects while offering improved outcomes for patients. |
| Growth in Investments for Research and Development Activities | To provide new diagnostic methods and treatment, there has been an increase in fundings and investments by government as well as non-governmental organizations. |
Global Hemoglobinopathies Market Segmentation
Market Breakup by Hemoglobinopathy Type
- Sickle Cell Disease
- Thalassemia
- Other Hemoglobinopathies
The report offers an insight into types of hemoglobinopathies. It majorly constitutes sickle cell disease, and thalassemia among others.
Market Breakup by Diagnosis Type
- DNA Testing
- Hemoglobin Electrophoresis
- Complete Blood Count (CBC)
- Prenatal Testing
- Newborn Screening
- Others
Based on types of diagnostics, the report is segmented into DNA testing, hemoglobin electrophoresis, complete blood count (CBC), prenatal testing, newborn screening, and others.
Market Breakup by Treatment Type
- Blood Transfusion
- Bone Marrow Transplantation
- Gene Therapy
- Iron Chelation Therapy
- Others
The hemoglobinopathies market growth is driven by the development of advanced treatments. The report provides a detailed breakup of treatment types, which includes blood transfusion, blood marrow transplantation, gene therapy, iron chelation therapy and others. Each treatment type is deployed based on the condition and severity of the condition in patients.
Market Breakup by End User
- Hospitals
- Diagnostic Laboratories
- Research Institutions
- Blood Banks
- Others
The report offers an analysis on the basis of end users as well. Hospitals, diagnostic laboratories, research institutions, blood banks among others are amongst key end users. Each section holds significant value, owing to rising expenditures in the healthcare domain.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to dominate the hemoglobinopathies market share. The market size can be attributed to the presence of major healthcare providers in the region, undergoing significant collaborations and acquisitions to devise the best treatment solutions. With high investments to improve the healthcare and research infrastructure, Asia Pacific is poised to experience rapid market growth.
Global Hemoglobinopathies Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- GlaxoSmithKline plc
- Bluebird Bio, Inc.
- Sanofi
- F. Hoffmann-La Roche Ltd.
- Acceleron Pharma, Inc.
- Emmaus Life Sciences, Inc.
- Celon Pharma S.A.
- AstraZeneca plc
- Mast Therapeutics, Inc. (Now known as BeyondSpring)
- Pfizer Inc.
- Cipla Inc.
- Bristol Myers Squibb Company
- Juno Therapeutics (Acquired by Bristol Myers Squibb)
- Emmaus Medical, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Hemoglobinopathy Type |
|
| Breakup by Diagnosis Type |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Hemoglobinopathies Market Report
- What is the market landscape expected to evolve in coming years?
- What is the incidence and epidemiology of hemoglobinopathies across various regions?
- Which section of the population is most susceptible to develop the condition?
- What are the key drivers and trends contributing to hemoglobinopathies market growth?
- What major constraints and challenges are affecting the market?
- What latest technologies are being used to treat hemoglobinopathies?
- Which diagnostic method is expected to lead the market share?
- What are the recent drug approvals for hemoglobinopathies treatment?
- Which companies are involved in developing most advanced treatment options for patients?
- What major collaborations and mergers are expected to transform the market during the forecast period?
- What are the major hemoglobinopathies treatment methods are being practiced in the market?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Hemoglobinopathies Market Overview
3.1 Global Hemoglobinopathies Market Historical Value (2017-2023)
3.2 Global Hemoglobinopathies Market Forecast Value (2024-2032)
4 Global Hemoglobinopathies Market Landscape*
4.1 Global Hemoglobinopathies: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Hemoglobinopathies: Product Landscape
4.2.1 Analysis by Hemoglobinopathy Type
4.2.2 Analysis by Diagnosis Type
5 Global Hemoglobinopathies Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Hemoglobinopathies Market Segmentation (2017-2032)
6.1 Global Hemoglobinopathies Market (2017-2032) by Hemoglobinopathy Type
6.1.1 Market Overview
6.1.2 Sickle Cell Disease
6.1.3 Thalassemia
6.1.4 Other Hemoglobinopathies
6.2 Global Hemoglobinopathies Market (2017-2032) by Diagnosis Type
6.2.1 Market Overview
6.2.2 DNA Testing
6.2.3 Hemoglobin Electrophoresis
6.2.4 Complete Blood Count (CBC)
6.2.5 Prenatal Testing
6.2.6 Newborn Screening
6.2.7 Others
6.3 Global Hemoglobinopathies Market (2017-2032) by Treatment Type
6.3.1 Market Overview
6.3.2 Blood Transfusion
6.3.3 Bone Marrow Transplantation
6.3.4 Gene Therapy
6.3.5 Iron Chelation Therapy
6.3.6 Others
6.4 Global Hemoglobinopathies Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Diagnostic Laboratories
6.4.4 Research Institutions
6.4.5 Blood Banks
6.4.6 Others
6.5 Global Hemoglobinopathies Market (2017-2032) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Hemoglobinopathies Market (2017-2032)
7.1 North America Hemoglobinopathies Market (2017-2032) by Hemoglobinopathy Type
7.1.1 Market Overview
7.1.2 Sickle Cell Disease
7.1.3 Thalassemia
7.1.4 Other Hemoglobinopathies
7.2 North America Hemoglobinopathies Market (2017-2032) by Diagnosis Type
7.2.1 Market Overview
7.2.2 DNA Testing
7.2.3 Hemoglobin Electrophoresis
7.2.4 Complete Blood Count (CBC)
7.2.5 Prenatal Testing
7.2.6 Newborn Screening
7.2.7 Others
7.3 North America Hemoglobinopathies Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Hemoglobinopathies Market (2017-2032)
8.1 Europe Hemoglobinopathies Market (2017-2032) by Hemoglobinopathy Type
8.1.1 Market Overview
8.1.2 Sickle Cell Disease
8.1.3 Thalassemia
8.1.4 Other Hemoglobinopathies
8.2 Europe Hemoglobinopathies Market (2017-2032) by Diagnosis Type
8.2.1 Market Overview
8.2.2 DNA Testing
8.2.3 Hemoglobin Electrophoresis
8.2.4 Complete Blood Count (CBC)
8.2.5 Prenatal Testing
8.2.6 Newborn Screening
8.2.7 Others
8.3 Europe Hemoglobinopathies Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Hemoglobinopathies Market (2017-2032)
9.1 Asia Pacific Hemoglobinopathies Market (2017-2032) by Hemoglobinopathy Type
9.1.1 Market Overview
9.1.2 Sickle Cell Disease
9.1.3 Thalassemia
9.1.4 Other Hemoglobinopathies
9.2 Asia Pacific Hemoglobinopathies Market (2017-2032) by Diagnosis Type
9.2.1 Market Overview
9.2.2 DNA Testing
9.2.3 Hemoglobin Electrophoresis
9.2.4 Complete Blood Count (CBC)
9.2.5 Prenatal Testing
9.2.6 Newborn Screening
9.2.7 Others
9.3 Asia Pacific Hemoglobinopathies Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Hemoglobinopathies Market (2017-2032)
10.1 Latin America Hemoglobinopathies Market (2017-2032) by Hemoglobinopathy Type
10.1.1 Market Overview
10.1.2 Sickle Cell Disease
10.1.3 Thalassemia
10.1.4 Other Hemoglobinopathies
10.2 Latin America Hemoglobinopathies Market (2017-2032) by Diagnosis Type
10.2.1 Market Overview
10.2.2 DNA Testing
10.2.3 Hemoglobin Electrophoresis
10.2.4 Complete Blood Count (CBC)
10.2.5 Prenatal Testing
10.2.6 Newborn Screening
10.2.7 Others
10.3 Latin America Hemoglobinopathies Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Hemoglobinopathies Market (2017-2032)
11.1 Middle East and Africa Hemoglobinopathies Market (2017-2032) by Hemoglobinopathy Type
11.1.1 Market Overview
11.1.2 Sickle Cell Disease
11.1.3 Thalassemia
11.1.4 Other Hemoglobinopathies
11.2 Middle East and Africa Hemoglobinopathies Market (2017-2032) by Diagnosis Type
11.2.1 Market Overview
11.2.2 DNA Testing
11.2.3 Hemoglobin Electrophoresis
11.2.4 Complete Blood Count (CBC)
11.2.5 Prenatal Testing
11.2.6 Newborn Screening
11.2.7 Others
11.3 Middle East and Africa Hemoglobinopathies Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Novartis AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 GlaxoSmithKline plc
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bluebird Bio, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sanofi
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 F. Hoffmann-La Roche Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Acceleron Pharma, Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Emmaus Life Sciences, Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Celon Pharma S.A.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 AstraZeneca plc
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Mast Therapeutics, Inc. (Now known as BeyondSpring)
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Pfizer Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Cipla Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Bristol Myers Squibb Company
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Juno Therapeutics (Acquired by Bristol Myers Squibb)
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Emmaus Medical, Inc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Hemoglobinopathies Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 6.9 billion in 2023 driven by the increasing incidence of sickle cell anemia and thalassemia across the globe.
The market is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032, likely to reach a market value of USD 15.9 billion by 2032.
The market demand is driven by rising expenditures in improving research and healthcare infrastructure to develop precise treatment alternatives for patients. Increasing collaborations between key market players is also contributing to the demand.
Growing application of gene therapy to offer precise and personalised treatment to affected individuals is a notable market trend. In December 2023, the United States FDA approved Exa-cel, the first CRISPR treatment for sickle cell disease.
Based on types, the market is divided into sickle cell disease, thalassemia, and others.
Major end users include hospitals, diagnostic laboratories, research institutions, blood banks and others.
Blood transfusion, bone marrow transplantation, gene therapy, iron chelation therapy and others are common treatments available in the market.
The common diagnostic methods include DNA testing, hemoglobin electrophoresis, complete blood count (CBC), prenatal testing, newborn screening, and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Novartis AG, GlaxoSmithKline plc, Bluebird Bio, Inc., Sanofi, F. Hoffmann-La Roche Ltd., Acceleron Pharma, Inc., Emmaus Life Sciences, Inc., Celon Pharma S.A., AstraZeneca plc, Mast Therapeutics, Inc. (Now known as BeyondSpring), Pfizer Inc., Cipla Inc., Juno Therapeutics (Acquired by Bristol Myers Squibb), Emmaus Medical, Inc., and Bristol Myers Squibb Company.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER